How many patients with transthyretin amyloid cardiomyopathy (or ATTR-CM) are still hiding in plain sight in our clinics?  Too often, the challenge is not confirming the diagnosis but suspecting it early enough.  

 
Following on from a recent interactive Experts Knowledge Share webinar, this suite of resources brings together clinical insight and patient perspective to help close that gap. 

 

Cardiologist Dr Philippe Debonnaire (Belgium) joined patient advocate Keith Dares (Canada), who lives with ATTR-CM himself, to help create this comprehensive educational programme.    

 

Explore this collection of resources, as two experts discuss the recognition and diagnosis of ATTR-CM from both clinical and patient perspectives.  

 

You'll hear about the red flags that should raise suspicion, the current diagnostic pathway and tools available today, and the barriers that can delay diagnosis in real-world practice. 

 

This is the full webinar replay. Watch the highlights from the conversation in the Highlights tab, or scroll down for the podcast and HCP infographic and patient infographic to use in your practice.

 

Clinical takeaways

  • ATTR-CM is under-recognised and frequently misdiagnosed, resulting in delayed diagnosis and treatment initiation
  • Recognising the red flags of ATTR-CM is essential for referral and for establishing diagnosis using the diagnostic algorithm
  • Early diagnosis includes screening in at-risk populations
  • Be aware of the red flags associated with ATTR-CM for earlier suspicion of the disease
  • Understand the current diagnostic pathway and key diagnostic tools used in the evaluation of ATTR-CM
  • Recognise barriers to ATTR-CM diagnosis and apply insights from a patient advocate to clinical practice 

Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).

 

Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands). 

 

Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE). 

 

Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia. 

 

He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.

Dr Philippe Debonnaire (MD, PhD, FESC) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: AstraZeneca, Alnylam, Bayer, Pfizer

Advisory board: AstraZeneca, Alnylam, Bayer, Pfizer

Amyloid research grants: AstraZeneca, Pfizer

PI amyloid (randomised controlled) trials and studies: Alexion – AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR, Intellia Therapeutics, Ionis, Novo Nordisk

Keith Dares is the Founder and President of The Amyloidosis Awareness Project Inc., a Canadian not-for-profit organisation dedicated to increasing awareness and recognising the symptoms of amyloidosis.

 

Now retired, Keith’s professional career included work as a Registered Nurse (BScN) followed by two decades with the Nova Scotia Department of Health and Wellness, where he contributed to policy, legislation, and health-system administration.

 

Keith became involved in the amyloidosis community following his diagnosis of wild-type ATTR cardiac amyloidosis (wtATTR-CM) in 2015 at the age of 55. His lived experience spans a period of profound change in the amyloidosis landscape: from a time when no therapies were available, to participating in a clinical trial, to now benefitting from an approved treatment accessible in Canada.

 

His current work focuses on improving the diagnostic journey for amyloidosis patients by promoting earlier recognition, timely access to appropriate therapies, and better long-term outcomes. He is committed to raising awareness among medical communities in Canada and internationally, emphasising the critical role of education leading to increased awareness to reduce diagnostic delays.

 

Keith shares his insights from 11 years of lived experience with amyloidosis. Owing to one physician’s experience with amyloidosis, he received an accurate diagnosis within nine weeks of presentation of symptoms, (when the average time to diagnosis for wild-type amyloidosis was five to seven years). Keith strongly believes that awareness is the key to enabling earlier treatment and improving patient outcomes.

Mr Keith Dares has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: Alnylam, AstraZeneca

Steering committee consultancy fee: Alnylam, AstraZeneca

Advisory board: Alnylam, AstraZeneca

Manuscript development: Alnylam, AstraZeneca

Travel grants: Alnylam

How many patients with transthyretin amyloid cardiomyopathy (or ATTR-CM) are still hiding in plain sight in our clinics?  Too often, the challenge is not confirming the diagnosis but suspecting it early enough.  

 
Following on from a recent interactive Experts Knowledge Share webinar, this suite of resources brings together clinical insight and patient perspective to help close that gap. 

 

Cardiologist Dr Philippe Debonnaire (Belgium) joined patient advocate Keith Dares (Canada), who lives with ATTR-CM himself, to help create this comprehensive educational programme.    

 

Explore this collection of resources, as two experts discuss the recognition and diagnosis of ATTR-CM from both clinical and patient perspectives.  

 

You'll hear about the red flags that should raise suspicion, the current diagnostic pathway and tools available today, and the barriers that can delay diagnosis in real-world practice. 

 

These are the highlights from the conversation. Watch the full webinar replay via the Full Video tab or scroll down to listen to the podcast and download the HCP infographic and patient infographic to use in your practice.

 

Clinical takeaways

  • ATTR-CM is under-recognised and frequently misdiagnosed, resulting in delayed diagnosis and treatment initiation
  • Recognising the red flags of ATTR-CM is essential for referral and for establishing diagnosis using the diagnostic algorithm
  • Early diagnosis includes screening in at-risk populations
  • Be aware of the red flags associated with ATTR-CM for earlier suspicion of the disease
  • Understand the current diagnostic pathway and key diagnostic tools used in the evaluation of ATTR-CM
  • Recognise barriers to ATTR-CM diagnosis and apply insights from a patient advocate to clinical practice 

Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).

 

Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands). 

 

Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE). 

 

Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia. 

 

He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.

Dr Philippe Debonnaire (MD, PhD, FESC) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: AstraZeneca, Alnylam, Bayer, Pfizer

Advisory board: AstraZeneca, Alnylam, Bayer, Pfizer

Amyloid research grants: AstraZeneca, Pfizer

PI amyloid (randomised controlled) trials and studies: Alexion – AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR, Intellia Therapeutics, Ionis, Novo Nordisk

Keith Dares is the Founder and President of The Amyloidosis Awareness Project Inc., a Canadian not-for-profit organisation dedicated to increasing awareness and recognising the symptoms of amyloidosis.

 

Now retired, Keith’s professional career included work as a Registered Nurse (BScN) followed by two decades with the Nova Scotia Department of Health and Wellness, where he contributed to policy, legislation, and health-system administration.

 

Keith became involved in the amyloidosis community following his diagnosis of wild-type ATTR cardiac amyloidosis (wtATTR-CM) in 2015 at the age of 55. His lived experience spans a period of profound change in the amyloidosis landscape: from a time when no therapies were available, to participating in a clinical trial, to now benefitting from an approved treatment accessible in Canada.

 

His current work focuses on improving the diagnostic journey for amyloidosis patients by promoting earlier recognition, timely access to appropriate therapies, and better long-term outcomes. He is committed to raising awareness among medical communities in Canada and internationally, emphasising the critical role of education leading to increased awareness to reduce diagnostic delays.

 

Keith shares his insights from 11 years of lived experience with amyloidosis. Owing to one physician’s experience with amyloidosis, he received an accurate diagnosis within nine weeks of presentation of symptoms, (when the average time to diagnosis for wild-type amyloidosis was five to seven years). Keith strongly believes that awareness is the key to enabling earlier treatment and improving patient outcomes.

Mr Keith Dares has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: Alnylam, AstraZeneca

Steering committee consultancy fee: Alnylam, AstraZeneca

Advisory board: Alnylam, AstraZeneca

Manuscript development: Alnylam, AstraZeneca

Travel grants: Alnylam

Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Watch the video now
Share this programme
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
Supporter Acknowledgement
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
I agree that this programme:

Was valuable to me

1/3
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Watch the video now
Share this programme
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
Supporter Acknowledgement
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
I agree that this programme:

Was valuable to me

1/3

For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322

How many patients with transthyretin amyloid cardiomyopathy (or ATTR-CM) are still hiding in plain sight in our clinics?  Too often, the challenge is not confirming the diagnosis but suspecting it early enough.  

 
Following on from a recent interactive Experts Knowledge Share webinar, this suite of resources brings together clinical insight and patient perspective to help close that gap. 

 

Cardiologist Dr Philippe Debonnaire (Belgium) joined patient advocate Keith Dares (Canada), who lives with ATTR-CM himself, to help create this comprehensive educational programme.    

 

Explore this collection of resources, as two experts discuss the recognition and diagnosis of ATTR-CM from both clinical and patient perspectives.  

 

You'll hear about the red flags that should raise suspicion, the current diagnostic pathway and tools available today, and the barriers that can delay diagnosis in real-world practice. 

 

This is the video podcast; you can also listen on Spotify or Apple. Watch the full webinar replay via the Full Video tab or scroll down to download the HCP infographic and patient infographic to use in your practice.

 

Clinical takeaways

  • ATTR-CM is under-recognised and frequently misdiagnosed, resulting in delayed diagnosis and treatment initiation
  • Recognising the red flags of ATTR-CM is essential for referral and for establishing diagnosis using the diagnostic algorithm
  • Early diagnosis includes screening in at-risk populations
  • Be aware of the red flags associated with ATTR-CM for earlier suspicion of the disease
  • Understand the current diagnostic pathway and key diagnostic tools used in the evaluation of ATTR-CM
  • Recognise barriers to ATTR-CM diagnosis and apply insights from a patient advocate to clinical practice 

Transcript to go here

Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).

 

Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands). 

 

Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE). 

 

Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia. 

 

He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.

Dr Philippe Debonnaire (MD, PhD, FESC) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: AstraZeneca, Alnylam, Bayer, Pfizer

Advisory board: AstraZeneca, Alnylam, Bayer, Pfizer

Amyloid research grants: AstraZeneca, Pfizer

PI amyloid (randomised controlled) trials and studies: Alexion – AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR, Intellia Therapeutics, Ionis, Novo Nordisk

Keith Dares is the Founder and President of The Amyloidosis Awareness Project Inc., a Canadian not-for-profit organisation dedicated to increasing awareness and recognising the symptoms of amyloidosis.

 

Now retired, Keith’s professional career included work as a Registered Nurse (BScN) followed by two decades with the Nova Scotia Department of Health and Wellness, where he contributed to policy, legislation, and health-system administration.

 

Keith became involved in the amyloidosis community following his diagnosis of wild-type ATTR cardiac amyloidosis (wtATTR-CM) in 2015 at the age of 55. His lived experience spans a period of profound change in the amyloidosis landscape: from a time when no therapies were available, to participating in a clinical trial, to now benefitting from an approved treatment accessible in Canada.

 

His current work focuses on improving the diagnostic journey for amyloidosis patients by promoting earlier recognition, timely access to appropriate therapies, and better long-term outcomes. He is committed to raising awareness among medical communities in Canada and internationally, emphasising the critical role of education leading to increased awareness to reduce diagnostic delays.

 

Keith shares his insights from 11 years of lived experience with amyloidosis. Owing to one physician’s experience with amyloidosis, he received an accurate diagnosis within nine weeks of presentation of symptoms, (when the average time to diagnosis for wild-type amyloidosis was five to seven years). Keith strongly believes that awareness is the key to enabling earlier treatment and improving patient outcomes.

Mr Keith Dares has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: Alnylam, AstraZeneca

Steering committee consultancy fee: Alnylam, AstraZeneca

Advisory board: Alnylam, AstraZeneca

Manuscript development: Alnylam, AstraZeneca

Travel grants: Alnylam

Programme summary
Listen to the podcast now
Share this programme
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
Supporter Acknowledgement
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
I agree that this programme:

Was valuable to me

1/3

How many patients with transthyretin amyloid cardiomyopathy (or ATTR-CM) are still hiding in plain sight in our clinics?  Too often, the challenge is not confirming the diagnosis but suspecting it early enough.  

 
Following on from a recent interactive Experts Knowledge Share webinar, this suite of resources brings together clinical insight and patient perspective to help close that gap. 

 

Cardiologist Dr Philippe Debonnaire (Belgium) joined patient advocate Keith Dares (Canada), who lives with ATTR-CM himself, to help create this comprehensive educational programme.    

 

Explore this collection of resources, as two experts discuss the recognition and diagnosis of ATTR-CM from both clinical and patient perspectives.  

 

You'll hear about the red flags that should raise suspicion, the current diagnostic pathway and tools available today, and the barriers that can delay diagnosis in real-world practice. 

 

View/download the HCP infographic and the patient infographic to use in your practice. Scroll up to watch the Full Video of the webinar and the conversation Highlights video, and to listen to the podcast on your preferred podcast platform.

 

Clinical takeaways

  • ATTR-CM is under-recognised and frequently misdiagnosed, resulting in delayed diagnosis and treatment initiation
  • Recognising the red flags of ATTR-CM is essential for referral and for establishing diagnosis using the diagnostic algorithm
  • Early diagnosis includes screening in at-risk populations
  • Be aware of the red flags associated with ATTR-CM for earlier suspicion of the disease
  • Understand the current diagnostic pathway and key diagnostic tools used in the evaluation of ATTR-CM
  • Recognise barriers to ATTR-CM diagnosis and apply insights from a patient advocate to clinical practice 

Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).

 

Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands). 

 

Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE). 

 

Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia. 

 

He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.

Dr Philippe Debonnaire (MD, PhD, FESC) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: AstraZeneca, Alnylam, Bayer, Pfizer

Advisory board: AstraZeneca, Alnylam, Bayer, Pfizer

Amyloid research grants: AstraZeneca, Pfizer

PI amyloid (randomised controlled) trials and studies: Alexion – AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR, Intellia Therapeutics, Ionis, Novo Nordisk

Keith Dares is the Founder and President of The Amyloidosis Awareness Project Inc., a Canadian not-for-profit organisation dedicated to increasing awareness and recognising the symptoms of amyloidosis.

 

Now retired, Keith’s professional career included work as a Registered Nurse (BScN) followed by two decades with the Nova Scotia Department of Health and Wellness, where he contributed to policy, legislation, and health-system administration.

 

Keith became involved in the amyloidosis community following his diagnosis of wild-type ATTR cardiac amyloidosis (wtATTR-CM) in 2015 at the age of 55. His lived experience spans a period of profound change in the amyloidosis landscape: from a time when no therapies were available, to participating in a clinical trial, to now benefitting from an approved treatment accessible in Canada.

 

His current work focuses on improving the diagnostic journey for amyloidosis patients by promoting earlier recognition, timely access to appropriate therapies, and better long-term outcomes. He is committed to raising awareness among medical communities in Canada and internationally, emphasising the critical role of education leading to increased awareness to reduce diagnostic delays.

 

Keith shares his insights from 11 years of lived experience with amyloidosis. Owing to one physician’s experience with amyloidosis, he received an accurate diagnosis within nine weeks of presentation of symptoms, (when the average time to diagnosis for wild-type amyloidosis was five to seven years). Keith strongly believes that awareness is the key to enabling earlier treatment and improving patient outcomes.

Mr Keith Dares has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: Alnylam, AstraZeneca

Steering committee consultancy fee: Alnylam, AstraZeneca

Advisory board: Alnylam, AstraZeneca

Manuscript development: Alnylam, AstraZeneca

Travel grants: Alnylam

How many patients with transthyretin amyloid cardiomyopathy (or ATTR-CM) are still hiding in plain sight in our clinics?  Too often, the challenge is not confirming the diagnosis but suspecting it early enough.  

 
Following on from a recent interactive Experts Knowledge Share webinar, this suite of resources brings together clinical insight and patient perspective to help close that gap. 

 

Cardiologist Dr Philippe Debonnaire (Belgium) joined patient advocate Keith Dares (Canada), who lives with ATTR-CM himself, to help create this comprehensive educational programme.    

 

Explore this collection of resources, as two experts discuss the recognition and diagnosis of ATTR-CM from both clinical and patient perspectives.  

 

You'll hear about the red flags that should raise suspicion, the current diagnostic pathway and tools available today, and the barriers that can delay diagnosis in real-world practice. 

 

View/download the patient infographic and HCP infographic to use in your practice. Scroll up to watch the Full Video of the webinar and the conversation Highlights video, and to listen to the podcast on your preferred podcast platform.

 

Clinical takeaways

  • ATTR-CM is under-recognised and frequently misdiagnosed, resulting in delayed diagnosis and treatment initiation
  • Recognising the red flags of ATTR-CM is essential for referral and for establishing diagnosis using the diagnostic algorithm
  • Early diagnosis includes screening in at-risk populations
  • Be aware of the red flags associated with ATTR-CM for earlier suspicion of the disease
  • Understand the current diagnostic pathway and key diagnostic tools used in the evaluation of ATTR-CM
  • Recognise barriers to ATTR-CM diagnosis and apply insights from a patient advocate to clinical practice 

Philippe Debonnaire (MD, PhD, FESC) graduated as cardiologist and obtained a Masters degree in Sports Medicine, both at Leuven University (Belgium).

 

Subsequently, he obtained a PhD, based on non-invasive cardiac imaging research at Leiden University Medical Hospital (the Netherlands). 

 

Since 2013 he works as cardiologist (interventional echocardiographist) in Sint-Jan Hospital Bruges (Belgium) with clinical and scientific focus on (advanced) echocardiographic techniques (3D, strain, stress, TOE). 

 

Apart from valvular and structural heart disease, his current focus includes cardiac amyloidosis, with ongoing publications and lecturing on (inter)national podia. 

 

He is immediate BWGNICI past-president, current EACVI Scientific Committee board member (former EACVI HIT and Education Committee positions), responsible for the echocardiography imaging fellowship in his centre.

Dr Philippe Debonnaire (MD, PhD, FESC) has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: AstraZeneca, Alnylam, Bayer, Pfizer

Advisory board: AstraZeneca, Alnylam, Bayer, Pfizer

Amyloid research grants: AstraZeneca, Pfizer

PI amyloid (randomised controlled) trials and studies: Alexion – AstraZeneca Rare Disease, Alnylam, AstraZeneca, Bayer, BridgeBio, Bruges Cardiac Amyloidosis Registry, Eidos, ICAR, Intellia Therapeutics, Ionis, Novo Nordisk

Keith Dares is the Founder and President of The Amyloidosis Awareness Project Inc., a Canadian not-for-profit organisation dedicated to increasing awareness and recognising the symptoms of amyloidosis.

 

Now retired, Keith’s professional career included work as a Registered Nurse (BScN) followed by two decades with the Nova Scotia Department of Health and Wellness, where he contributed to policy, legislation, and health-system administration.

 

Keith became involved in the amyloidosis community following his diagnosis of wild-type ATTR cardiac amyloidosis (wtATTR-CM) in 2015 at the age of 55. His lived experience spans a period of profound change in the amyloidosis landscape: from a time when no therapies were available, to participating in a clinical trial, to now benefitting from an approved treatment accessible in Canada.

 

His current work focuses on improving the diagnostic journey for amyloidosis patients by promoting earlier recognition, timely access to appropriate therapies, and better long-term outcomes. He is committed to raising awareness among medical communities in Canada and internationally, emphasising the critical role of education leading to increased awareness to reduce diagnostic delays.

 

Keith shares his insights from 11 years of lived experience with amyloidosis. Owing to one physician’s experience with amyloidosis, he received an accurate diagnosis within nine weeks of presentation of symptoms, (when the average time to diagnosis for wild-type amyloidosis was five to seven years). Keith strongly believes that awareness is the key to enabling earlier treatment and improving patient outcomes.

Mr Keith Dares has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker/consultancy fee: Alnylam, AstraZeneca

Steering committee consultancy fee: Alnylam, AstraZeneca

Advisory board: Alnylam, AstraZeneca

Manuscript development: Alnylam, AstraZeneca

Travel grants: Alnylam

Programme summary
Share this programme
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
Supporter Acknowledgement
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
I agree that this programme:

Was valuable to me

1/3
Programme summary
Share this programme
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
Supporter Acknowledgement
For healthcare professionals only. Developed and funded by Alnylam Switzerland GmbH and organised in collaboration with COR2ED Medical Affairs. The webinar focused on disease awareness and diagnosis; treatments and specific medicinal products were not discussed. TTR-INTX-00322
I agree that this programme:

Was valuable to me

1/3

Other programmes of interest